Compare Genuine Parts Company (GPC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs IDEXX Laboratories, Inc. — how do they compare? Genuine Parts Company trades at $125.44 (market cap $16.65B), while IDEXX Laboratories, Inc. trades at $575.45 (market cap $43.94B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.6× Genuine Parts Company's market cap, and Genuine Parts Company pays a 3.51% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| GPC | IDXX | |
|---|---|---|
Market Cap | $16.65B | $43.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $766.68 |
52-Week Low | $92.47 | $514.61 |
Enterprise Value | $22.87B | $44.84B |
Dividend Yield | 3.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $125.40, up 2.65% with a bullish technical signal. The stock shows mixed fundamentals with a high P/E ratio of 275 but strong gross margins of 36.87%. Recent earnings beat expectations in Q1 2026 after two consecutive misses, with Q2 2026 results expected July 21. Analyst consensus is mixed with 43% buy ratings and a $133 price target, while technical indicators show support at $119-120 and resistance at $122-124.
GPC presents a cautious opportunity with dividend stability but faces profitability challenges. The 70-year dividend growth history provides income appeal, though net margins below 1% and declining cash flow trends warrant monitoring. Upside exists if Q2 earnings beat expectations, but weak profitability and rising debt-to-asset ratios pose significant risks to shareholder value.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
